Older patients with acute myloid leukemia patients show promising response in drug study
Two Virginia Tech engineers have put bacteria to work as tiny weavers of biomaterials and medical implants. Paul Gatenholm and Rafael Davalos, faculty members with the Virginia Tech Wake Forest University School of Biomedical Engineering, have developed a new technology for controlling the motion of bacteria that produce cellulose. The use of bacterial cellulose (BC)
Full Post: New technology to control the motion of bacteria that produce cellulose - biomaterial and medical implant potential
Older patients with acute myloid leukemia (AML) who were once told that nothing could be done for them are finding new hope - and life - through a clinical trial at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.Preliminary findings of the phase II study suggest that older, previously untreated AML patients can achieve complete remission at a higher than expected rate when treated with the drug decitabine using a novel dosing schedule.
“This study could provide a new treatment paradigm for elderly patients with AML,” says co-author Dr. John Byrd, associate director of translational research at Ohio State’s Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
The study will be a poster presentation at the 50th Annual Meeting of the American Society of Hematology in San Francisco on Monday (12/8).
About 13,300 new cases of AML are expected this year in the United States. It is a rapidly progressive disease that results in the accumulation of immature, functionless cells in the marrow and blood, leaving the body unable to fight infections or produce enough normal red blood cells, white blood cells and platelets. The disease primarily affects people age 60 and older and is the second most common form of leukemia in adults.
Most elderly AML patients diagnosed today are offered only supportive care because their bodies are believed to be too weak to withstand the effects of chemotherapy treatment, says principal investigator Dr. William Blum, a hematologist and oncologist and researcher at Ohio State.
“The treatment of AML is difficult in anybody, but particularly for older patients who don’t tolerate the ‘thunderbolt’ of intensive chemotherapy well,” says Blum. “Some of the patients we are treating successfully had previously been told by other physicians to ‘go home and die.’ They were judged not to be candidates for any treatment at all because they likely would not survive the traditional, harsh chemotherapy approach.”
“The development of a less toxic therapy may enable this ’silent majority’ of patients who never receive treatment today to actually benefit from prolonged remissions with improved quality and length of life, without paying the price exacted by today’s intensive therapy regimens,” says Blum.
This ongoing study involves 33 patients age 60 to 83. A total of 58 percent of patients responded, including 42 percent who achieved complete remission. In some cases, Blum says, patients who achieved remission were then able to receive bone marrow transplants designed to further improve their chances for cure, as part of another clinical trial of transplantation specifically designed for older AML patients.
On the decitabine trial, patients received the intravenous drug for one hour a day for 10 consecutive days each month until the leukemia was gone. Subsequent cycles of the drug were given for three to five days, customized for each patient based on clinical response or toxicity.
“Results have been extremely promising, with high remission rates,” says senior investigator Dr. Guido Marcucci, a researcher and medical oncologist at Ohio State’s Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute. “This research reveals the potential for a paradigm shift in the treatment of AML away from highly toxic drugs to a much less toxic alternative.”
A drug once dismissed as ineffective in patients with chronic lymphocytic leukemia (CLL) has shown promising results in two phase I and II clinical trials, according to researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute. Together, the trials involved 116 patients with advanced CLL who were
Full Post: Dismissed leukemia drug flavopiridol helps chronic lymphocytic leukemia patients
Biopure Corporation has announced that it has submitted to the Food and Drug Administration (FDA) an investigational new drug (IND) application to conduct a pilot phase 2 clinical trial of the company’s oxygen therapeutic Hemopure [hemoglobin glutamer - 250 (bovine)]. In the proposed trial Hemopure would be studied for use in the treatment of life-threatening
Full Post: Biopure submits IND for trial in patients with acute myeloid leukemia
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML). The first patient was enrolled by Eric Feldman, MD at the Weill Medical College of Cornell University and New York Presbyterian Hospital. Dr.
Full Post: Celator Pharmaceuticals enrols first patient in phase 2 study of CPX-351 in acute myeloid leukemia
Biothera has announced today it began dosing patients in the second arm of its metastatic colorectal cancer (mCRC) trial in August. This arm of the trial is evaluating the combination therapy of its lead drug candidate, Imprime PGG, with Erbitux, an anti-cancer monoclonal antibody from ImClone Systems. Unlike the first trial arm, the second treatment
Full Post: Biothera initiates second phase of metastatic colorectal cancer trial
Sunesis Pharmaceuticals, Inc. presented data from three clinical trials of the company’s lead drug candidate, voreloxin (formerly SNS-595), at the Chemotherapy Foundation Symposium held in New York on November 4-8. Data previously presented from Phase 1 and Phase 1b/2 studies in patients with acute myeloid leukemia (AML) showed that preliminary clinical responses were observed in
Full Post: Sunesis Pharmaceuticals presents data of Voreloxin in patients with acute myeloid leukemia and ovarian cancer